Update on Scheduled FDA Advisory Committee Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St to open higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Mesoblast (MESO) Receives Backing from FDA Panel for Remestemcel-L
August 13, 2020 5:05 PM EDTMesoblast (NASDAQ: MESO) Receives Backing from FDA Panel for Remestemcel-L
FDA ADCOMM VOTE: Do the available data support the efficacy of remestemcel-L in pediatric patients with steroid-refractory aGVHD?
8-Yes
2-No
0-Abstain
aGVHD = acute graft-versus-host disease$MESO #Ryoncil #MesenchymalStromalCells #StemCellTherapy
... More
Despite Concerns, Cantor Fitzgerald Thinks Mesoblast's (MESO) Ryoncil Could Be Approved
August 11, 2020 8:19 AM EDTCantor Fitzgerald analyst Louis Chen weighed in on Mesoblast Limited (NASDAQ: MESO) after shares were slammed 25%+ following FDA briefing documents that raised the "Fear Factor" about Ryoncil, in the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) in children. Chen thinks Ryoncil could be approved despite the fears.
The FDA AdCom for MESO's Ryoncil is on 8/13 from 8am to 5pm ET. The FDA's Oncologic Drugs... More
